TheProfitWatch

AUPH - Aurinia Pharmaceuticals Inc

Day 1m 10m 60m PreMarket Market AfterHours Gap
15.1 0.63 (4.14%) 0.0 (0.03%) 0.0 (0.0%) 0.05 (0.32%) -0.07 (-0.46%) 0.61 (4.0%) -0.01 (-0.07%) -0.18 (-1.18%)

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: Market

Earnings & Ratios

Basic EPS:
0.16
Diluted EPS:
0.16
Basic P/E:
98.2813
Diluted P/E:
98.2813
RSI(14) 1m:
57.14
VWAP:
15.72
RVol:

Events

Period Kind Movement Occurred At

Related News